|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0019704,
umls-concept:C0020964,
umls-concept:C0020971,
umls-concept:C0026724,
umls-concept:C0026809,
umls-concept:C0030956,
umls-concept:C0040808,
umls-concept:C0205373,
umls-concept:C0442118,
umls-concept:C0443252,
umls-concept:C0913822,
umls-concept:C0913823,
umls-concept:C1274040
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2004-11-23
|
|
pubmed:abstractText |
An intranasal DNA vaccine prime followed by a gp41 peptide booster immunization was compared with gp41 peptide and control immunizations. Serum HIV-1-specific IgG and IgA as well as IgA in feces and vaginal and lung secretions were detected after immunizations. Long-term humoral immunity was studied for up to 12 mo after the booster immunization by testing the presence of HIV-1 gp41- and CCR5-specific Abs and IgG/IgA-secreting B lymphocytes in spleen and regional lymph nodes in immunized mice. A long-term IgA-specific response in the intestines, vagina, and lungs was obtained in addition to a systemic immune response. Mice immunized only with gp41 peptides and L3 adjuvant developed a long-term gp41-specific serum IgG response systemically, although over a shorter period (1-9 mo), and long-term mucosal gp41-specific IgA immunity. HIV-1-neutralizing serum Abs were induced that were still present 12 mo after booster immunization. HIV-1 SF2-neutralizing fecal and lung IgA was detectable only in the DNA-primed mouse groups. Intranasal DNA prime followed by one peptide/L3 adjuvant booster immunization, but not a peptide prime followed by a DNA booster, was able to induce B cell memory and HIV-1-neutralizing Abs for at least half of a mouse's life span.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0022-1767
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
173
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7078-89
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15557206-AIDS Vaccines,
pubmed-meshheading:15557206-Administration, Intranasal,
pubmed-meshheading:15557206-Amino Acid Sequence,
pubmed-meshheading:15557206-Animals,
pubmed-meshheading:15557206-B-Lymphocytes,
pubmed-meshheading:15557206-Bronchoalveolar Lavage Fluid,
pubmed-meshheading:15557206-Feces,
pubmed-meshheading:15557206-Female,
pubmed-meshheading:15557206-HIV Antibodies,
pubmed-meshheading:15557206-HIV Envelope Protein gp160,
pubmed-meshheading:15557206-HIV Envelope Protein gp41,
pubmed-meshheading:15557206-HIV-1,
pubmed-meshheading:15557206-Immunity, Active,
pubmed-meshheading:15557206-Immunity, Mucosal,
pubmed-meshheading:15557206-Immunization, Secondary,
pubmed-meshheading:15557206-Immunoglobulin A,
pubmed-meshheading:15557206-Immunoglobulin G,
pubmed-meshheading:15557206-Immunologic Memory,
pubmed-meshheading:15557206-Intestine, Small,
pubmed-meshheading:15557206-Mice,
pubmed-meshheading:15557206-Mice, Inbred C57BL,
pubmed-meshheading:15557206-Molecular Sequence Data,
pubmed-meshheading:15557206-Nasal Mucosa,
pubmed-meshheading:15557206-Neutralization Tests,
pubmed-meshheading:15557206-T-Lymphocytes,
pubmed-meshheading:15557206-Vaccines, DNA,
pubmed-meshheading:15557206-Vaccines, Subunit,
pubmed-meshheading:15557206-Vagina
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.
|
|
pubmed:affiliation |
Swedish Institute for Infectious Disease Control and Microbiology and Tumorbiology Center, Department of Virology, Karolinska Institute, Solna, Sweden.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
